Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 84

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 87
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Combretastatin A-4 Analogs as Anticancer Agents
University of Arkansas for Medical Sciences United States flag United States
Abstract ID: 2013-25, 2014-14, and 201
Combretastatin A-4 Analogs as Anticancer Agents...
Contact Nancy M. Gray
Email me a copy of this message

Microtubule-binding agents (MBAs) which destabilize microtubules and promote depolymerization interfere with the mitotic spindle assembly during cell division resulting in cell death. This is the main reason for utilizing such molecules as anti-cancer agents. A natural product, combretastatin A-4 (CA-4), isolated from the bark of the South African tree Combretum caffrum is a well-established microtubule binding agent. From structure-activity relationship (SAR) studies, the cis-orientation of the trimethoxyphenyl ring system on the double bond of the CA-4 molecule is essential for the cytotoxic effects of this compound. However, even though CA-4 is a potent microtubule binding agent, it possesses disadvantages such as vascular disruption, low solubility, and isomerization to the less active trans-isomer (trans-CA-4) in solution. Four novel series of combretastatin A-4 analogs have been designed and several compounds have been synthesized in each series. These series include benzothiophene acrylonitrile analogs, heterocyclic (2H)-1,2,3-triazoles analogs, aromatic and heteroaromatic analogs, and tetrazole analogs.

Several compounds from each series exhibited potent cytotoxic activity against various human cancer cell lines. Select compounds were evaluated in a tubulin polymerization assay and were found to inhibit tubulin polymerization.

Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development EARLY STAGE